"The high mortality rate from cervical cancer globally can be reduced through a comprehensive approach that includes prevention, early diagnosis, effective screening and treatment programs. There are currently vaccines that protect against common cancer-causing types of HPV and can significantly reduce the risk of cervical cancer." 1
-World Health Organisation
TESTING PARADIGMS AND CHALLENGES
BD – Addressing the challenges in HPV primary screening
The BD Onclarity™ HPV Assay answers the needs for primary HPV screening in the post-vaccination era. It offers extended genotyping that supports risk stratification and persistence monitoring.
The BD COR™ System enhances both laboratory outcomes and patient management with advanced molecular diagnostic capabilities. It offers a solution for high volume labs with a large on-board sample and reagent storage capacity to reduce hands-on and increase walk-away time.6
The BD Viper™ System is a benchtop system ideal for small to medium volume labs.